학술논문
Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease.
Document Type
Article
Author
Source
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2021 Supplement S9, Vol. 17, p1-2, 2p
Subject
Language
ISSN
15525260